Kyntra Bio, Inc. (KYNB)
NASDAQ: KYNB · Real-Time Price · USD
7.12
-0.01 (-0.14%)
Mar 11, 2026, 2:19 PM EDT - Market open
Kyntra Bio Employees
Kyntra Bio had 225 employees as of December 31, 2024. The number of employees decreased by 261 or -53.70% compared to the previous year.
Employees
225
Change (1Y)
-261
Growth (1Y)
-53.70%
Revenue / Employee
$36,880
Profits / Employee
$958,462
Market Cap
28.80M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 225 | -261 | -53.70% |
| Dec 31, 2023 | 486 | -106 | -17.91% |
| Dec 31, 2022 | 592 | 26 | 4.59% |
| Dec 31, 2021 | 566 | -33 | -5.51% |
| Dec 31, 2020 | 599 | 68 | 12.81% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| IGC Pharma | 70 |
| Passage Bio | 60 |
| Evaxion | 46 |
| Cue Biopharma | 41 |
| NeuroSense Therapeutics | 17 |
| BriaCell Therapeutics | 16 |
| Hyperion DeFi | 14 |
| RenovoRx | 10 |
KYNB News
- 2 days ago - Kyntra Bio to Report Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 15 days ago - What's Going On With Kyntra Bio Stock Tuesday? - Benzinga
- 15 days ago - Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026 - GlobeNewsWire
- 21 days ago - Kyntra Bio to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum - GlobeNewsWire
- 4 months ago - FibroGen, Inc. (FGEN) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 months ago - FibroGen to Report Third Quarter 2025 Financial Results - GlobeNewsWire
- 6 months ago - FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer - GlobeNewsWire